Please login to the form below

sarcoma

This page shows the latest sarcoma news and features for those working in and with pharma, biotech and healthcare.

breast, lung, sarcoma, gastric, bladder, endometrial, ovarian and oesophageal cancers.

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Authorisation revoked for Lartruvo. Friday’s ruling was also notable for the CHMP’s decision to revoke the marketing authorisation for Eli Lilly’s sarcoma treatment Lartruvo, after the drug failed
Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme. Eli Lilly is to withdraw its soft tissue sarcoma treatment Lartruvo from the market after it failed a post-marketing efficacy study. ... Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer.
Positive data unlocks more EIB funding for Nanobiotix

as well as an independent assessment of the clinical benefit/risk ratio for NBTXR3 in a phase 3 programme in soft tissue sarcoma (STS).
Trulicity’s ascent lifts Lilly

The drug is approved in the US for patients with the NTRK gene mutation, most commonly seen in cancers of the salivary gland, thyroid, lung and soft tissue sarcoma, with EU
EMA says Lilly’s Lartruvo should not be prescribed

Lilly claimed EMA approval for Lartruvo (olaratumab) for the first-line treatment of advanced soft tissue sarcoma (STS) in 2016, when it became the first new drug for patients with the

More from news
Approximately 5 fully matching, plus 45 partially matching documents found.

Europe vs the US: New drug product approvals

Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’s annual conference.
Pharma deals during February 2014

Also, this month Merck &Co has handed back the rights to Ariad Pharmaceutical's ridaforolimus, a mTOR inhibitor in a phase III trial for advanced sarcoma.
Interview: Harvey Berger and Timothy Clackson, Ariad

And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the front-runner in the company's pipeline

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

World AIDS Day 2018: Fighting the stigma surrounding HIV

2. Characterised by very low levels of CD4+ T cells, and the presence of AIDS-related pathologies (such as tuberculosis and Kaposi’s sarcoma), the diagnosis of AIDS marks just how

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.